The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.

The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

The firms will distribute NowDx's First to Know test to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers, and safety net clinics.

NEW YORK — Laboratory Corporation of America and NowDiagnostics (NowDx) said Tuesday that they have launched an initiative to distribute NowDx's First to Know Syphilis test at no cost to ...